Plasma Transfusion in Liver Transplantation - Full Text View

Purpose

The aim of the study is to compare the clinical efficacy of three types of plasma secured on the viral level either by quarantine or by chemical treatment in patients undergoing liver transplantation.

Condition	Intervention	Phase
Bleeding in Liver Transplantation	Drug: plasma	Phase IV

MedlinePlus related topics:

Blood Transfusion and Donation Liver Transplantation

ChemIDplus related topics:

Methylene blue

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Efficacy Study

Official Title:	Plasma Transfusion in Liver Transplantation : a Randomized, Double Blind, Multicenter Trial of Methylene Blue, Solvent/Detergent and Quarantined Plasma.

Further study details as provided by Etablissement Français du Sang:

Primary Outcome Measures:

volume equivalence between the 3 types of transfused plasma

Secondary Outcome Measures:

correction of coagulation abnormalities
immediate and delayed adverse events

Estimated Enrollment:	300
Study Start Date:	June 2005
Estimated Study Completion Date:	December 2007

Detailed Description:

Three types of plasma are transfused in bleeding patients undergoing liver transplantation:

quarantined plasma,
methylene blue treated plasma,
solvent/detergent plasma. The main purpose is to show that the volume of methylene blue treated plasma consumed intraoperatively is equivalent to that of the 2 other types of plasma.

In addition, the correction of coagulation abnormalities are studied.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

age 18 yo and above
consent is signed,
liver transplantation is indicated,
plasma is transfused

Exclusion Criteria:

multiorgan transplantation (except combined kidney and liver transplantation)
allergy to methylene blue.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00235183

Contacts


Contact: Françoise Courtois, MD	33 1 44 49 66 07	francoise.courtois@efs.sante.fr

Contact: Anne Chabanel, ScD	33 1 44 49 66 14	anne.chabanel@efs.sante.fr

Locations


France
	EFS	Recruiting
	Paris, France, 75015
	Contact: Françoise Courtois, MD 33 1 44 49 66 07 francoise.courtois@efs.sante.fr
	Contact: Anne Chabanel, ScD 33 1 44 49 66 14 anne.chabanel@efs.sante.fr
	Principal Investigator: Françoise Courtois, MD

Sponsors and Collaborators

Etablissement Français du Sang

Investigators


Principal Investigator:	Yves Ozier, MD, PhD	Hôpital Cochin, Paris, France

Principal Investigator:	Emmanuel Samain, MD, PhD	hôpital Jean Minjoz, Besançon, France

Principal Investigator:	Marie - Christine Gillon, MD	Hôpital Paul Brousse, Villejuif, France

Principal Investigator:	Loïc Villalon, MD	Hôpital Pontchaillou

More Information

Study ID Numbers:	EFS plasma trial
First Received:	October 6, 2005
Last Updated:	October 5, 2006
ClinicalTrials.gov Identifier:	NCT00235183
Health Authority:	France: Afssaps - French Health Products Safety Agency

Keywords provided by Etablissement Français du Sang:

plasma

bleeding

liver transplantation

Study placed in the following topic categories:

Hemorrhage

Methylene Blue

ClinicalTrials.gov processed this record on October 10, 2008

Sponsored by:	Etablissement Français du Sang
Information provided by:	Etablissement Français du Sang
ClinicalTrials.gov Identifier:	NCT00235183